Synairgen (FRA:OMY) Growth Rank : 0 (As of Mar. 31, 2025)

View and export this data going back to 2020. Start your Free Trial

What is Synairgen Growth Rank?

Synairgen has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Synairgen Growth Rank Related Terms

Thank you for viewing the detailed overview of Synairgen's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Synairgen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synairgen PLC (FRA:OMY) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

SYGGF:USA SNG:UK

Address

Southampton General Hospital, Tremona Road, Mailpoint 810, Level F, South Block, Southampton, GBR, SO16 6YD

Website

https://www.synairgen.com

Synairgen PLC is a United Kingdom-based respiratory drug discovery and development company. The company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in areas, including severe asthma, kidney fibrosis, cardiac fibrosis, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis. The company's Programmes include SNG001, SG016, SG018, and others.

Synairgen Headlines

No Headlines